NEW RADIOPHARMACEUTICALS BASED ON PROSTATE-SPECIFIC INHIBITORS OF MEMBRANE ANTIGEN FOR DIAGNOSTICS AND THERAPY OF METASTATIC PROSTATE CANCER

Cover Page


Cite item

Full Text

Abstract

About 10.7% cases of prostate cancer were registered in Russia in 2011 (40 000 patients). More than half of cancer cases were revealed in advanced (III–IV) stages when metastases inevitably developed quickly. Clinical problem of early diagnostics and treatment of metastatic prostate cancer is still not solved. Anatomical imaging techniques have low sensitivity and specificity for the detection of this disease. Metabolic visualization methods which use prostate specific antigen (PSA) as a marker are also ineffective. This article describes prostate-specific membrane antigens (PSMA) that are proposed as a marker for diagnostics and therapy of prostate cancer. The most promising PSMA-based radiopharmaceutical agent for diagnostics has been developed and clinically tested in the European countries. These pharmaceuticals are based on small peptide molecules modified with urea, and have the highest affinity to PSMA. Favorable pharmacokinetics, rapid accumulation in the tumor and rapid excretion from the body are beneficial features of these pharmaceuticals.

 

 

About the authors

O. P. Vlasova

State Scientific Centre of the Russian Federation «Institute for Physics and Power Engineering n.a. A.I. Leypunsky», Obninsk, Russian Federation

Author for correspondence.
Email: ovlasova@ippe.ru

кандидат биологических наук, советник по ядерной медицине директора отделения
физико-химических технологий ГНЦ «Физико-энергетический институт им. А.И. Лейпунского»
Адрес: 249033, Калужская обл., Обнинск, пл. Бондаренко, д. 1, тел.: +7 (484) 399-40-12

Россия

K. E. German

A.N. Frumkin Institute of Physical Chemistry and Electrochemistry RAS, Moscow, Russian Federation

Email: guerman_k@mail.ru

кандидат химических наук, заведующий лабораторией химии технеция ИФХЭ РАН
Адрес: 119071, Москва, Ленинский пр-т, д. 31, корп. 4, тел.: +7 (495) 335-20-04

Россия

V. V. Krylov

A. Cyb Scientific Research Centre of Radiology, Obninsk, Russian Federation

Email: krylov@mrrc.obninsk.ru

доктор медицинских наук, руководитель отделения радиохирургического лечения
открытыми радионуклидами МРНЦ им. А.Ф. Цыба (филиал ФМИЦ им. П.А.Герцена)
Адрес: 249031, Калужская обл., Обнинск, ул. Жукова, д. 10

Россия

V. M. Petriev

A. Cyb Scientific Research Centre of Radiology, Obninsk, Russian Federation

Email: petriev@mrrc.obninsk.ru

 Россия

N. B. Epshtein

National Research Nuclear University MEPhI, Obninsk, Russian Federation

Email: nbepshtejn@mephi.ru

доктор фармацевтических наук, доцент, заведующая кафедрой фармацевтической и
радиофармацевтической химии ИАТЭ НИЯУ «МИФИ»
Адрес: 249040, Калужская обл., Обнинск, Студгородок, д. 1, тел.: +7 (484) 397-94-90, доб. 252

Россия

References

  1. Klinicheskie rekomendatsii Evropeiskoi assotsiatsii urologov. Per. s angl. K.A. Shiranova [Clinical Guidelines of the European Association of Urology. Trans. from English by K.A. Shiranov]. Moscow; 2011. 162 p.
  2. Veliev E.I., Sokolov E.A., Ivkin E.V. New in hormonotherapy of prostate cancer. Prakticheskaya onkologiya = Practical oncology. 2012;13(3):151–155.
  3. Rusakov I.G., Gritskevich A.A. Modern views on the treatment of castrate-resistant prostate cancer. Prakticheskaya onkologiya = Practical oncology. 2012;13(3):156–165.
  4. Korenev I.V. Stsintigrafiya prostaty s 99mTc-tekhnetrilom v rannei dobiopsiinoi diagnostike raka predstatel'noi zhelezy. Avtoref. dis… kand. med. nauk [Prostate Scintigraphy with 99mTc-technetril in Early Pre-Bioptic Diagnosis of Prostate Cancer. Author’s abstract]. Chelyabinsk; 2009. 25 p.
  5. Khmara T.G. Informativnost' sovremennykh metodov diagnostiki raka predstatel'noi zhelezy. Avtoref. dis… kand. med. nauk [Informative Modern Methods of Diagnosis of Prostate Cancer. Author’s abstract]. Saratov; 2010. 26 p.
  6. Apolo A.B., Pandit-Taskar N., Morris M.J. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer. J. Nucl. Med. 2008; 49: 2031–2041.
  7. Saylor P.J., Mahmood U., Kunawudhi A., Smith M.R., Mat-thew R.S., Edwin L. Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2012; 53 (11): 1670–1675. doi: 10.2967/jnumed.112.105007.
  8. Afshar-Oromieh A., Haberkorn U., Schlemmer H.P., Fenchel M., Eder M., Eisenhut M., Hadaschik B.A., Kopp-Schneider A., Röthke M. Comparison of PET imaging with a 68Ga labeled PSMA ligand and 18F choline based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014; 41: 11–20.
  9. Vorob'ev N.A. Localized prostate cancer: a view radiologist. Prakticheskaya onkologiya = Practical oncology. 2012;13(3):211–218.
  10. Cho S.Y., Gage K.L., Mease R.C., Senthamizhchelvan S., Holt D.P., Jeffrey-Kwanisai A., Endres C.J., Dannals R.F., Sgouros G., Lodge M., Eisenberger M.A., Rodriguez R., Carducci M.A., Rojas C., Slusher B.S., Kozikowski A.P., Pomper M.G. Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F DCFBC, a low-molecular-weight Inhibitor of Prostate Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. J. Nucl. Med. 2012; 53: 1883–1891. Available at: http://jnm.snmjournals.org/ content/53/12/1883.full
  11. Osborne J.R., Akhtar N.H., Vallabhajosula Sh., Anand A., Deh K., Tagawa S.T. Prostate specific membrane antigen based imaging. Urol. Oncol. 2013; 31 144–154.
  12. Bogomolov O.A., Shkol'nik M.I., Zharinov G.M. Clinical and prognostic value of changes in the levels of prostate-specific antigen prior to the treatment of patients with prostate cancer. Abstracts of VIII congress of oncologists and radiologists of CIS and Eurasia. Evraziiskii onkologicheskii zhurnal = Eurasian journal of oncology. 2014;673–674.
  13. Sardana G., Dowell B., Diamandis E.P. Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer. Clin. Chemistry. 2008; 54 (12): 1951–1960.
  14. Jadvar H., Desai B., Ji L., Conti P.S., Dorff Т.В., Groshen S., Pin-ski J. and Quinn D. Baseline 18F — ФДГ PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate Resistant Metastatic Prostate Cancer. J. Nucl. Med. 2013; 54: 1195–1201.
  15. Mease R.C., Foss C.A., Pomper M.G. PET imaging in prostate cancer: focus on prostate specific membrane antigen. Curr. Top. Med. Chem. 2013; 13 (8): 951–962.
  16. Hillier S.M., Maresca K.P, Lu G., Merkin R.D, Marquis J.C., Zim-merman C.N., Eckelman W.C., Joyal J.L. and Babich J.W. 99mTc-Labeled Small Molecule Inhibitors of Prostate Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. J. Nucl. Med. 2013; 54: 1369–1376.
  17. Babich D.U., Tsimmerman K., Dzhoyal Dzh., Mareska K.P., Lu G. Zayavka na patent № 2011127468/04 ot 04.12.2009 (RF № 2539584) «Kompleksy tekhnetsiya i reniya s bis (geteroarilami) i sposoby ikh primeneniya». Opubl. 20.01.2015 g. [Patent № 2011127468/04 (RF number 2539584) "Technetium and Rhenium Complexes with Bis (Heteroaryl) and Methods for their Application" dated 04.12.2009. Published 01.20.2015].
  18. Pomper M.G., Mis R.Ch., Chen I. Zayavka napatent № 2011107752/04 ot 31.07.2009 (RU 2 494 096 C2) «Agenty, svyazyvayushchiesya s PSMA i ikh primenenie». Opubl. 10.09.2012 g. [Application for Patent № 2011107752/04 (RU 2494096 C2) «Agents that Bind to PSMA and their Application" dated 31.07.2009. Published 10.09.2012].
  19. Genliang L., Maresca K.P., Hillier S.M., Zimmerman C.N., Eckelman W.C., Joyal J.L., Babich J.W. Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorganic & Med. Chem. Lett. 2013; 23: 1557–1563.
  20. Nosov A.K., Reva S.A., Vorob'ev A.V. Possibilities of individualization of drug treatment urological and oncological patients. Prakticheskaya onkologiya = Practical oncology. 2013;14(4):232–238.
  21. German K.E., Vlasova O.P., Nerozin N.A., Kodina G.E., Maruk A.Ya., Petriev V.M., Skvortsov V.G., Epstein N.B., Airapetova N.G. Interdisciplinary consortium collaboration for the development of radiopharmaceutical approach for effective diagnostics and therapy of prostate cancer in Russia. Abstracts of the 8th International Symposium on Technetium and Rhenium: Science and Utilization. September 29th to October 3rd 2014. France. P. 191–192.
  22. Vlasova O.P., Nerozin N.A., Shapovalov V.V., Dunin A.V., Stepchenkov D.V., Kham'yanov S.V. Meditsinskie radioizotopy, radiofarmpreparaty i izdeliya meditsinskoi tekhniki FGUP «GNTs RF FEI». Sostoyanie i perspektivy. Mat-ly mezhdunar. III Foruma: «Innovatsii v meditsine: osnovnye problemy i puti ikh resheniya» [Medical Radioisotopes, Radiopharmaceuticals and Medical Equipment FSUE "IPPE". Status and Prospects. Materials of 3RD Intern. Forum "Innovations in Medicine: Main Problems and Ways to solve them"]. Novosibirsk, Novosibirskii akademicheskii tsentr cheloveka, 2014. P. 151–158.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies